Loading...
•
Dec 31, 2022
Alnylam Q4 2022 Earnings Report
Alnylam reported strong commercial execution and pipeline advancements.
Key Takeaways
Alnylam Pharmaceuticals reported Q4 2022 financial results, with global net product revenues reaching $262 million, contributing to a full-year revenue of $894 million, a 35% increase compared to 2021. The company highlighted the acceptance of its sNDA for ONPATTRO and provided 2023 combined net product revenue guidance of $1,200 million to $1,285 million.
Global net product revenues for Q4 2022 reached $262 million, and full-year revenues reached $894 million, representing a 35% annual growth compared to 2021.
The sNDA for ONPATTRO for the treatment of the cardiomyopathy of ATTR amyloidosis submitted and accepted.
Combined net product revenue guidance for 2023 is projected to be between $1,200 million and $1,285 million.
AMVUTTRA launch has demonstrated a great start in its first two full quarters on the market.
Alnylam
Alnylam
Alnylam Revenue by Segment
Revenue by Segment
ONPATTRO Revenue
CapyFin.comGIVLAARI Revenue
CapyFin.comAMVUTTRA Revenue
CapyFin.comOXLUMO Revenue
CapyFin.com Forward Guidance
Alnylam anticipates combined net product revenues between $1,200 million and $1,285 million for 2023, along with revenues from collaborations and royalties between $100 million and $175 million. The company projects GAAP R&D and SG&A expenses between $1,790 million and $1,885 million, and non-GAAP R&D and SG&A expenses between $1,575 million and $1,650 million.
Positive Outlook
- Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021
- Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO are expected to be between $1,200 million and $1,285 million for full year 2023.
- Net Product Revenue Growth vs. 2022 at reported Fx rates is expected to be 34% to 44% for full year 2023.
- Net revenues from collaborations and royalties are expected to be between $100 million – $175 million for full year 2023.
- Submitted and Received Acceptance of Supplemental New Drug Application (sNDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Challenges Ahead
- GAAP R&D and SG&A expenses are expected to be between $1,790 million – $1,885 million for full year 2023.
- Non-GAAP R&D and SG&A expenses are expected to be between $1,575 million – $1,650 million for full year 2023.
- Assumes U.S. sNDA approval of patisiran for ATTR amyloidosis with cardiomyopathy by the PDUFA date on October 8, 2023.
- Excludes $215-$235 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income